CRISPR THERAPEUTICS AG Payments to Acquire Marketable Securities
CRISPR THERAPEUTICS AG (CRSP) reported Payments to Acquire Marketable Securities of $952.39 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-03
- CRISPR THERAPEUTICS AG payments to acquire marketable securities for the quarter ending 2026-06-30 was $206.30M, a 1.94% decline year-over-year.
- CRISPR THERAPEUTICS AG payments to acquire marketable securities for the quarter ending 2026-03-31 was $746.09M, a 271.69% increase year-over-year.
- CRISPR THERAPEUTICS AG payments to acquire marketable securities for the quarter ending 2025-12-31 was $262.97M, a 0.44% decline year-over-year.
- CRISPR THERAPEUTICS AG payments to acquire marketable securities for the quarter ending 2025-09-30 was $334.09M, a 16.80% decline year-over-year.
- CRISPR THERAPEUTICS AG payments to acquire marketable securities for fiscal 2025 was $1.01B, a 31.10% decline from fiscal 2024.
- CRISPR THERAPEUTICS AG payments to acquire marketable securities for fiscal 2024 was $1.46B, a 37.27% increase from fiscal 2023.
- CRISPR THERAPEUTICS AG payments to acquire marketable securities for fiscal 2023 was $1.07B, a 24.82% decline from fiscal 2022.
- CRISPR THERAPEUTICS AG payments to acquire marketable securities for fiscal 2022 was $1.42B, a 6.06% decline from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $206.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $952.39M 10-Q · filed 2026-08-03 | $1.22B derived: sum of 3 quarters · filed 2026-08-03 | $1.55B derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $746.09M 10-Q · filed 2026-05-04 | $1.01B derived: sum of 2 quarters · filed 2026-05-04 | $1.34B derived: sum of 3 quarters · filed 2026-05-04 | $1.55B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $262.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $597.06M derived: sum of 2 quarters · filed 2026-02-12 | $807.44M derived: sum of 3 quarters · filed 2026-08-03 | $1.01B 10-K · filed 2026-02-12 |
| 2025-09-30 | $334.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $544.47M derived: sum of 2 quarters · filed 2026-08-03 | $745.20M 10-Q · filed 2025-11-10 | $1.01B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $210.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $411.11M 10-Q · filed 2026-08-03 | $675.24M derived: sum of 3 quarters · filed 2026-08-03 | $1.08B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $200.73M 10-Q · filed 2026-05-04 | $464.85M derived: sum of 2 quarters · filed 2026-05-04 | $866.42M derived: sum of 3 quarters · filed 2026-05-04 | $1.34B derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $264.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $665.69M derived: sum of 2 quarters · filed 2026-02-12 | $1.14B derived: sum of 3 quarters · filed 2026-02-12 | $1.46B 10-K · filed 2026-02-12 |
| 2024-09-30 | $401.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $872.16M derived: sum of 2 quarters · filed 2025-11-10 | $1.20B 10-Q · filed 2025-11-10 | $1.57B derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | $470.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $797.51M 10-Q · filed 2025-08-04 | $1.17B derived: sum of 3 quarters · filed 2026-02-12 | $1.41B derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | $326.92M 10-Q · filed 2025-05-06 | $695.06M derived: sum of 2 quarters · filed 2026-02-12 | $940.46M derived: sum of 3 quarters · filed 2026-02-12 | $1.13B derived: sum of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | $368.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $613.55M derived: sum of 2 quarters · filed 2026-02-12 | $800.28M derived: sum of 3 quarters · filed 2026-02-12 | $1.07B 10-K · filed 2026-02-12 |
| 2023-09-30 | $245.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $432.13M derived: sum of 2 quarters · filed 2024-11-05 | $697.76M 10-Q · filed 2024-11-05 | $1.19B derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-06-30 | $186.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $452.36M 10-Q · filed 2024-08-05 | $946.76M derived: sum of 3 quarters · filed 2025-02-11 | $1.27B derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-03-31 | $265.63M 10-Q · filed 2024-05-08 | $760.02M derived: sum of 2 quarters · filed 2025-02-11 | $1.09B derived: sum of 3 quarters · filed 2025-02-11 | $1.36B derived: sum of 4 quarters · filed 2025-02-11 |
| 2022-12-31 | $494.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | $820.66M derived: sum of 2 quarters · filed 2025-02-11 | $1.09B derived: sum of 3 quarters · filed 2025-02-11 | $1.42B 10-K · filed 2025-02-11 |
| 2022-09-30 | $326.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $600.26M derived: sum of 2 quarters · filed 2023-11-06 | $923.40M 10-Q · filed 2023-11-06 | $1.05B derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-06-30 | $274.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $597.14M 10-Q · filed 2023-08-07 | $719.68M derived: sum of 3 quarters · filed 2024-02-21 | $1.39B derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-03-31 | $323.14M 10-Q · filed 2022-05-09 | $445.68M derived: sum of 2 quarters · filed 2024-02-21 | $1.12B derived: sum of 3 quarters · filed 2024-02-21 | $1.51B derived: sum of 4 quarters · filed 2024-02-21 |
| 2021-12-31 | $122.54M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $793.35M derived: sum of 2 quarters · filed 2024-02-21 | $1.19B derived: sum of 3 quarters · filed 2024-02-21 | $1.51B 10-K · filed 2024-02-21 |
| 2021-09-30 | $670.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $1.06B derived: sum of 2 quarters · filed 2022-11-01 | $1.39B 10-Q · filed 2022-11-01 | $1.66B derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | $392.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $715.98M 10-Q · filed 2022-08-08 | $984.66M derived: sum of 3 quarters · filed 2023-02-21 | |
| 2021-03-31 | $323.98M 10-Q · filed 2022-05-09 | $592.66M derived: sum of 2 quarters · filed 2023-02-21 | ||
| 2020-12-31 | $268.68M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $594.00M 10-K · filed 2023-02-21 | ||
| 2020-09-30 | $325.32M 10-Q · filed 2021-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |